Table 3.
Primary and secondary clinical outcomes in AMI patients stratified by BMI at 1-year and 3-year.
| Group | P-value | Log rank P-value | HR (95% CI) | p-value | Adjusted HR (95%CI) | P-value | ||
|---|---|---|---|---|---|---|---|---|
| 1-year | ||||||||
| MACCE | Group 1 | 266 (10.1) | < 0.001 | < 0.001 | 2.270 (1.828–2.818) | < 0.001 | 1.274 (1.014–1.601) | 0.038 |
| Group 2 | 348 (6.5) | 1.415 (1.149–1.742) | 0.001 | 1.210 (0.980–1.495) | 0.077 | |||
| Group 3 | 119 (4.6) | 1.000 | 1.000 | |||||
| CD | Group 1 | 183 (7.0) | < 0.001 | < 0.001 | 3.345 (2.475–4.522) | < 0.001 | 1.518 (1.107–2.081) | 0.010 |
| Group 2 | 191 (3.6) | 1.673 (1.239–2.258) | 0.001 | 1.325 (0.976–1.799) | 0.072 | |||
| Group 3 | 55 (2.1) | 1.000 | 1.000 | |||||
| MI | Group 1 | 50 (1.9) | 0.143 | 0.091 | 1.597 (1.024–2.488) | 0.039 | 1.090 (0.677–1.756) | 0.723 |
| Group 2 | 79 (1.5) | 1.195 (0.792–1.801) | 0.396 | 1.082 (0.712–1.643) | 0.713 | |||
| Group 3 | 32 (1.3) | 1.000 | 1.000 | |||||
| TVR | Group 1 | 13 (0.5) | 0.334 | 0.417 | 0.636 (0.319–1.279) | 0.200 | 0.807 (0.381–1.709) | 0.575 |
| Group 2 | 39 (0.7) | 0.899 (0.529–1.529) | 0.695 | 1.008 (0.583–1.745) | 0.977 | |||
| Group 3 | 21 (0.8) | 1.000 | 1.000 | |||||
| CVA | Group 1 | 35 (1.3) | 0.053 | 0.037 | 2.107 (1.180–3.761) | 0.012 | 1.332 (0.719–2.467) | 0.362 |
| Group 2 | 60 (1.1) | 1.712 (0.999–2.933) | 0.050 | 1.468 (0.849–2.539) | 0.169 | |||
| Group 3 | 17 (0.7) | 1.000 | 1.000 | |||||
| AD | Group 1 | 263 (10.0) | < 0.001 | < 0.001 | 3.413 (2.651–4.394) | < 0.001 | 1.543 (1.184–2.011) | 0.001 |
| Group 2 | 267 (5.0) | 1.651 (1.283–2.124) | < 0.001 | 1.327 (1.026–1.717) | 0.031 | |||
| Group 3 | 78 (3.0) | 1.000 | 1.000 | |||||
| NEW-HF | Group 1 | 150 (5.7) | < 0.001 | < 0.001 | 1.967 (1.491–2.595) | < 0.001 | 1.073 (0.799–1.442) | 0.638 |
| Group 2 | 202 (3.8) | 1.290 (0.990–1.682) | 0.059 | 1.109 (0.846–1.452) | 0.454 | |||
| Group 3 | 75 (2.9) | 1.000 | 1.000 | |||||
| ST | Group 1 | 12 (0.5) | 0.082 | 0.070 | 4.066 (1.148–14.405) | 0.030 | 4.177 (1.095–15.940) | 0.036 |
| Group 2 | 19 (0.4) | 3.061 (0.906–10.340) | 0.072 | 3.263 (0.945–11.267) | 0.062 | |||
| Group 3 | 3 (0.1) | 1.000 | 1.000 | |||||
| Minor bleeding | Group 1 | 111 (4.2) | < 0.001 | < 0.001 | 1.992 (1.442–2.752) | < 0.001 | 1.784 (1.259–2.528) | 0.001 |
| Group 2 | 145 (2.7) | 1.264 (0.927–1.724) | 0.139 | 1.223 (0.891–1.677) | 0.213 | |||
| Group 3 | 55 (2.1) | 1.000 | 1.000 | |||||
| 3-year | ||||||||
| MACCE | Group 1 | 412 (15.7) | < 0.001 | < 0.001 | 2.097 (1.774–2.478) | < 0.001 | 1.230 (1.030–1.469) | 0.022 |
| Group 2 | 600 (11.2) | 1.416 (1.209–1.658) | < 0.001 | 1.217 (1.037–1.429) | 0.016 | |||
| Group 3 | 207 (8.1) | 1.000 | 1.000 | |||||
| CD | Group 1 | 271 (10.3) | < 0.001 | < 0.001 | 3.643 (2.828–4.692) | < 0.001 | 1.583 (1.215–2.062) | 0.001 |
| Group 2 | 274 (5.1) | 1.725 (1.340–2.221) | < 0.001 | 1.332 (1.030–1.721) | 0.029 | |||
| Group 3 | 77 (3.0) | 1.000 | 1.000 | |||||
| MI | Group 1 | 90 (3.4) | 0.196 | 0.074 | 1.446 (1.052–1.987) | 0.023 | 1.109 (0.787–1.563) | 0.556 |
| Group 2 | 167 (3.1) | 1.234 (0.928–1.641) | 0.148 | 1.141 (0.853–1.527) | 0.374 | |||
| Group 3 | 66 (2.6) | 1.000 | 1.000 | |||||
| TVR | Group 1 | 27 (1.0) | 0.066 | 0.139 | 0.682 (0.421–1.106) | 0.121 | 0.892 (0.529–1.504) | 0.668 |
| Group 2 | 90 (1.7) | 1.045 (0.725–1.508) | 0.813 | 1.182 (0.809–1.726) | 0.387 | |||
| Group 3 | 42 (1.6) | 1.000 | 1.000 | |||||
| CVA | Group 1 | 63 (2.4) | 0.146 | 0.061 | 1.596 (1.080–2.359) | 0.019 | 1.027 (0.676–1.560) | 0.902 |
| Group 2 | 115 (2.1) | 1.339 (0.940–1.906) | 0.106 | 1.182 (0.824–1.695) | 0.363 | |||
| Group 3 | 42 (1.6) | 1.000 | 1.000 | |||||
| AD | Group 1 | 417 (15.8) | < 0.001 | < 0.001 | 3.638 (2.970–4.457) | < 0.001 | 1.576 (1.274–1.949) | < .0001 |
| Group 2 | 430 (8.0) | 1.742 (1.423–2.133) | < 0.001 | 1.348 (1.097–1.655) | 0.004 | |||
| Group 3 | 120 (4.7) | 1.000 | 1.000 | |||||
| NEW-HF | Group 1 | 150 (5.7) | < 0.001 | < 0.001 | 1.967 (1.491–2.595) | < 0.001 | 1.073 (0.799–1.442) | 0.638 |
| Group 2 | 202 (3.8) | 1.290 (0.990–1.682) | 0.059 | 1.109 (0.846–1.452) | 0.454 | |||
| Group 3 | 75 (2.9) | 1.000 | 1.000 | |||||
| ST | Group 1 | 19 (0.7) | 0.725 | 0.591 | 1.433 (0.718–2.858) | 0.307 | 1.430 (0.671–3.047) | 0.354 |
| Group 2 | 35 (0.7) | 1.218 (0.655–2.264) | 0.532 | 1.296 (0.683–2.458) | 0.428 | |||
| Group 3 | 14 (0.6) | 1.000 | 1.000 | |||||
| Minor bleeding | Group 1 | 112 (4.3) | < 0.001 | < 0.001 | 2.010 (1.456–2.776) | < 0.001 | 1.804 (1.274–2.555) | 0.001 |
| Group 2 | 145 (2.7) | 1.264 (0.927–1.724) | 0.139 | 1.224 (0.892–1.679) | 0.211 | |||
| Group 3 | 55 (2.1) | 1.000 | 1.000 | |||||
Data are presented as n (%), CI confidence interval; HR hazard ratio. All of the variables in Table 3 were included and analyzed to perform univariate analysis. On the basis of the variables that were significant (P < 0.05) according to univariate analysis, a multivariate Cox proportional hazard model was constructed. CD cardiac death, AD all cause death except cardiac death, MI myocardial infarction, CVA cerebrovascular attack, TVR target vessel revascularization, ST stent thrombosis.